Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/28/2025 | $23.00 | Buy | Rodman & Renshaw |
| 10/21/2024 | $20.00 | Buy | Alliance Global Partners |
| 9/27/2024 | $18.00 | Outperform | Raymond James |
| 8/22/2024 | $22.00 | Sector Outperform | Scotiabank |
| 6/1/2023 | $16.00 | Outperform | Robert W. Baird |
| 5/24/2022 | $14.00 → $7.00 | Buy → Neutral | B. Riley Securities |
| 1/24/2022 | $32.00 → $20.00 | Buy | B. Riley Securities |
| 7/7/2021 | $32.00 → $42.00 | Buy | Maxim Group |
4 - Inmune Bio, Inc. (0001711754) (Issuer)
4 - Inmune Bio, Inc. (0001711754) (Issuer)
4 - Inmune Bio, Inc. (0001711754) (Issuer)
BOCA RATON, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announces its financial results for the quarter ended September 30, 2024 and provides a business update. Q3 2024 and Recent Corporate Highlights DN-TNF Platform Highlights (XPro™): Announced completion enrollment for its Phase 2 Alzheimer's Disease ("AD") trial on Friday, 27 September. This global, blinded, randomized Phase 2 trial (the "AD02 trial") is focused on patients with Early AD and biomarkers of elevated neuroinflammation.
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, Oct. 24, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer's Disease (AD), today announced that it will host a conference call on Thursday October 31, 2024, at 4:30pm EDT to discuss results for its quarter ended September 30, 2024 and to provide a corporate update. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the IN
Company to Host Conference Call Today, August 1, at 4:30pm ET BOCA RATON, Fla., Aug. 01, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company developing treatments that harness the patient's innate immune system to fight disease, today announces its financial results for the quarter ended June 30, 2024 and provides a business update. Q2 2024 and Recent Corporate Highlights DN-TNF Platform Highlights (XPro™): The Phase 2 randomized, blinded clinical trial for patients with Early Alzheimer's Disease is on schedule to reach its final enrollment before the end of Q3 followed by top-line data approximately six months fr
4 - Inmune Bio, Inc. (0001711754) (Issuer)
4 - Inmune Bio, Inc. (0001711754) (Issuer)
4 - Inmune Bio, Inc. (0001711754) (Issuer)
Boca Raton, Florida, May 30, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company, is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1st, according to a preliminary list of additions posted Friday, May 24th. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30th, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion
DURHAM, N.C., Nov. 15, 2021 (GLOBE NEWSWIRE) -- CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today announced the appointment of Dr. Ed Baracchini as chairman of the Company's board of directors. "As a member of the CoImmune board of directors, Dr. Baracchini has provided strong counsel and guidance on many important issues in corporate development and strategy," stated Dr. Charles Nicolette, chief executive officer. "In his new role as chairman, his depth of experience in both biotechnology and fundraising will provide new levels of insight and guidance as we seek to advance our novel pipeline o
Medical review of Phase 1 cohorts demonstrated no safety issuesData to be presented at the 10th Annual Innate Killer Summit, March 3-5 BOCA RATON, Fla, Feb. 12, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage immunology and inflammation company, continues to advance its Natural Killer (NK) cell therapy, INKmune™, in a Phase I/II trial (the "CaRe PC" trial) for men with metastatic castration-resistant prostate cancer (mCRPC). The Company is pleased to announce completion of the third and highest dose cohort of the Phase I portion of the trial allowing opening of the Phase II high dose cohort. The Scientific Review Committee (SRC) charter is to re
The Company reports results of a double-blinded, randomized, placebo-controlled study, known as "MissionEB," investigating CORDStrom for treatment of RDEB in pediatric patients, which evidence a favorable benefit-risk profile in support of the intended applications for marketing authorization. CORDStrom, developed by INmune Bio is a patent pending, off the shelf, advanced mesenchymal stromal cell (MSC) platform developed to treat complex inflammatory diseases that has significant clinical development advantages over current MSC products.FDA grants CORDStrom a Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) for treatment of epidermolysis bullosa (EB).Parallel effor
First patient treated in Phase II portion of clinical trial in metastatic prostate cancer at the West Los Angeles Veterans Administration Hospital Boca Raton, Florida, Jan. 28, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, has an ongoing Phase I/II trial in men with metastatic castration-resistant prostate cancer (mCRPC). The Company is pleased to announce the participation of a patient at the West Los Angeles VA Medical Center in the trial. The participant received the investigational intervention, as an out-p
SC 13G - Inmune Bio, Inc. (0001711754) (Subject)
SC 13G/A - Inmune Bio, Inc. (0001711754) (Subject)
SC 13G - Inmune Bio, Inc. (0001711754) (Subject)
8-K - Inmune Bio, Inc. (0001711754) (Filer)
8-K - Inmune Bio, Inc. (0001711754) (Filer)
8-K - Inmune Bio, Inc. (0001711754) (Filer)
Recently, on June 26, 2024, Director Juda Scott bought $36,350 worth of shares (5,000 units at $7.27) (SEC Form 4) in INmune Bio Inc. This insider purchase is significant as it indicates confidence from someone within the company towards its future growth prospects. It's interesting to note that this purchase by Juda Scott follows a series of transactions by other insiders in the company. For example, Moss David J bought $149,993 worth of shares (18,028 units at $8.32) on April 24, 2024, increasing direct ownership by 1% to 1,268,179 units. This demonstrates a consistent trend of insider buying within the organization. Looking back at previous transactions, on May 16, 2024, several key ins
Rodman & Renshaw initiated coverage of INmune Bio with a rating of Buy and set a new price target of $23.00
Alliance Global Partners initiated coverage of INmune Bio with a rating of Buy and set a new price target of $20.00
Raymond James initiated coverage of INmune Bio with a rating of Outperform and set a new price target of $18.00